Back to search results

Illuminate: CAR T-cell Therapy (BCB-276) for DIPG

This study, called Illuminate, is testing an investigational treatment called BCB-276 for children and young adults with Diffuse Intrinsic Pontine Glioma (DIPG), an aggressive brain tumor. BCB-276 is a CAR T-cell therapy, which means it uses your own immune cells that are specially trained to find and fight cancer. To join, you must be between 1 and 26 years old, have DIPG, and enroll within 6 weeks of finishing standard radiation therapy. The main goal is to see if BCB-276 can improve how long patients live (overall survival) after treatment. This study is currently recruiting 75 participants.

Study design
This is an interventional study planning to enroll 75 participants. All eligible participants will receive BCB-276, and outcomes will be compared to information from similar individuals with DIPG whose data have been collected in a registry.
What's involved
You would undergo a procedure called leukapheresis to collect your white blood cells, have BCB-276 manufactured, and receive treatment directly into the fluid-filled spaces of your brain approximately every 2 weeks for up to 15 doses over about 7-8 months.
Compensation
Not stated in the trial record.
Follow-up
Overall survival will be measured for up to 24 months from the date of enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07680439

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

Recruiting
PHASE2Ages 1–26InterventionalTreatment
BrainChild Bio, Inc
~75 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:BCB-276

At a glance

Recruiting sites
1 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Survival
Measured over Overall Survival (OS) as defined as time from the date of enrollment to death from any cause (up to 24 months from date of enrollment).

Conditions

Diffuse Intrinsic Pontine Glioma
DIPG
Brain Tumor
CNS Tumor
Central Nervous System Tumor
Pediatric Cancer
Adult Cancer Patients
CNS Tumor, Childhood
CNS Tumor, Adult
Brainstem Glioma
Diffuse Midline Glioma
DMG

Explore related trials

Diffuse Intrinsic Pontine GliomaCD276 wt Allele

NCT07680439

Where you'd take part

This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Children's Healthcare of Atlanta

    Atlanta, Georgiastudy coordinator listed

    Not yet recruiting

  • Children's Hospital Los Angeles

    Los Angeles, Californiastudy coordinator listed

    Not yet recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvaniastudy coordinator listed

    Not yet recruiting

  • Lurie Children's Hospital

    Chicago, Illinoisstudy coordinator listed

    Not yet recruiting

  • Nationwide Children's Hospital

    Columbus, Ohiostudy coordinator listed

    Not yet recruiting

  • Seattle Children's Hospital

    Seattle, Washingtonstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Cori Abikoff, MD · STUDY_DIRECTOR · BrainChild Bio, Inc

Who to contact

BrainChild Bio Study Team
[email protected]
425-569-8747
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must be aged 1 and ≤ 26 years and weigh ≥10kg.
Diagnosis of Diffuse Intrinsic Pontine Glioma (DIPG) based on imaging, with or without biopsy confirmation consistent with high-grade glioma or diffuse midline glioma
Able to tolerate leukapheresis and other study procedures in the opinion of the Investigator.
Central Nervous System (CNS) reservoir catheter present prior to first dose of study drug.
Participant must have completed standard radiation therapy within 6 weeks of enrollment for participation.
Performance Status of ≥ 60; mild to moderate restriction or better. Lansky (under 16 years of age) or Karnofsky (16 years of age or older).
Adequate organ function and overall clinical status to participate, including stable or improving neurologic symptoms.
Participants of childbearing/fathering potential must agree to use highly effective contraception from the time of enrollment through 12 months following the last T cell infusion.
Participants with ventriculoperitoneal (VP) shunts need to have a programable system and be able to tolerate temporary adjustment of the shunt required for study treatment.
Participant must meet all other health and safety criteria defined in the study protocol.
Participant and/or authorized legal representative willing to provide consent/assent for study participation, including participation in the 15-year long term follow up period.

Exclusion

Previous tumor-directed therapy or treatment-directed clinical study other than standard radiation with or without temozolamide.
Evidence of metastatic disease.
Requirement of high or increasing doses of corticosteroids prior to participation.
Severe swallowing difficulties or other significant clinical conditions that may interfere with participation.
Presence of an active malignancy other than DIPG.
Active or uncontrolled human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection based on protocol-required laboratory testing.
Pregnant or breastfeeding.
Presence of any condition that, in the Investigator's opinion, would prohibit the participant from undergoing treatment under this protocol.

What this trial measures

  • Overall SurvivalOverall Survival (OS) as defined as time from the date of enrollment to death from any cause (up to 24 months from date of enrollment).

    Up to 24 months from date of enrollment